Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Alpelisib→

Alpelisib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1217486-61-7
Molecular formula
C19H22F3N5O2S
Molecular weight
441.5 g/mol
Drug class
Phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitortargeted antineoplastic
Mechanism of action
Inhibits phosphatidylinositol-3-kinase with predominant activity against the alpha isoform (PI3Kα), including mutant p110α encoded by PIK3CA, reducing downstream AKT signalling and tumour-cell growth.
Indications / reported uses
  • In combination with fulvestrant for adults with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on or after an endocrine-based regimen
  • Treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) requiring systemic therapy in adults and paediatric patients aged 2 years and older under the US FDA Vijoice indication; the oncology and PROS formulations/labels are distinct

Sources: US FDA prescribing information — PIQRAY · US FDA prescribing information — VIJOICE · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Alpelisib Environmental Risk Assessment (ERA) (the Alpelisib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.